PMID- 38397275
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240227
IS  - 2227-9067 (Print)
IS  - 2227-9067 (Electronic)
IS  - 2227-9067 (Linking)
VI  - 11
IP  - 2
DP  - 2024 Jan 26
TI  - Atomoxetine Treatment of Attention Deficit/Hyperactivity Disorder Symptoms in 
      3-6-Year-Old Children with Autism Spectrum Disorder: A Retrospective Cohort 
      Study.
LID - 10.3390/children11020163 [doi]
LID - 163
AB  - Atomoxetine is indicated for the management of attention deficit/hyperactivity 
      disorder (ADHD) in children and adolescents aged 6 to 18 years. Few studies have 
      assessed the safety and tolerability of atomoxetine in younger patients. This 
      retrospective cohort study included 133 children aged 3-6 years who were 
      diagnosed with ADHD comorbid with autism spectrum disorder (ASD). The primary 
      endpoint was the evaluation of the safety profile of atomoxetine. In total, 50 
      patients (37.6%) experienced adverse events (AEs), which led to treatment 
      discontinuation in 23 patients (17.3%). The most common AEs were gastrointestinal 
      (24.1%), aggression or hostility (12.8%), and increased hyperactivity (9.0%). In 
      the 23 patients who discontinued treatment, all the AEs resolved after treatment 
      ceased. Among the 110 patients who completed at least 6 months' treatment, 
      atomoxetine titrated to a dose of 1.2-1.8 mg/kg/day appeared to be well tolerated 
      and effective. The Clinical Global Impression-Improvement score improved to 1 
      ("very much improved") and 2 ("much improved") in 62.4% and 20.3% of children, 
      respectively, at their last visit. Overall, atomoxetine appeared to be well 
      tolerated in younger children with comorbid ADHD and ASD. Nevertheless, close 
      patient monitoring remains essential, and the study limitations necessitate 
      caution in generalizing these findings to broader populations. Long-term 
      prospective studies are required.
FAU - Alsayouf, Hamza A
AU  - Alsayouf HA
AUID- ORCID: 0000-0002-3646-7599
AD  - Dr Hamza Alsayouf Clinic, Amman 11181, Jordan.
FAU - Alsarhan, Osama
AU  - Alsarhan O
AD  - Dr Hamza Alsayouf Clinic, Amman 11181, Jordan.
FAU - Khreisat, Wael
AU  - Khreisat W
AD  - Royal Medical Services, Amman 11855, Jordan.
FAU - Daoud, Azhar
AU  - Daoud A
AD  - The Specialty Hospital, Amman 11942, Jordan.
LA  - eng
PT  - Journal Article
DEP - 20240126
PL  - Switzerland
TA  - Children (Basel)
JT  - Children (Basel, Switzerland)
JID - 101648936
PMC - PMC10887200
OTO - NOTNLM
OT  - adverse events
OT  - atomoxetine
OT  - attention deficit/hyperactivity disorder
OT  - autism spectrum disorder
OT  - safety
COIS- The authors declare no conflicts of interest.
EDAT- 2024/02/24 11:44
MHDA- 2024/02/24 11:45
PMCR- 2024/01/26
CRDT- 2024/02/24 01:06
PHST- 2023/12/20 00:00 [received]
PHST- 2024/01/21 00:00 [revised]
PHST- 2024/01/24 00:00 [accepted]
PHST- 2024/02/24 11:45 [medline]
PHST- 2024/02/24 11:44 [pubmed]
PHST- 2024/02/24 01:06 [entrez]
PHST- 2024/01/26 00:00 [pmc-release]
AID - children11020163 [pii]
AID - children-11-00163 [pii]
AID - 10.3390/children11020163 [doi]
PST - epublish
SO  - Children (Basel). 2024 Jan 26;11(2):163. doi: 10.3390/children11020163.